It is therefore necessary that we develop novel‐targeted therapeutic strategies that enhance chemosensitivity of these tumor types and restore treatment effectiveness; the overwhelming representation of mutations involving abnormal activation of the PI3K/Akt/mTOR axis also provides a strong support for the use of pharmacological tools suppressing the functions of this molecular pathway. The gene discussed is AKT1; the disease is neoplasm.